Caspase-1, -4, -5, and -11 activate Gasdermin D (GSDMD) pores, causing pyroptotic cell death and the release of interleukin (IL)-1β and IL-18 1. Blocking this pathway holds therapeutic promise for the treatment of inflammatory disorders, but cell permeable caspase inhibitors have not been successful in clinical trials 2. Here, we describe covalent caspase inhibitors that selectively block pyroptosis and IL-1β secretion despite being excluded from healthy cells. These inhibitors did not prevent caspase-driven apoptosis, implying that GSDMD pores facilitated their uptake. Membrane-impermeable dyes entered the cells rescued from pyroptosis, consistent with transient membrane permeabilization by GSDMD pores. Caspase inhibition prevented rather than delayed cell death, consistent with membrane repair mechanisms neutralizing the initial GSDMD pores. Inhibiting caspase-1 and -11 suppressed IL-1β and IL-18 production in a mouse model of endotoxic shock, underscoring the therapeutic potential of exploiting GSDMD pores for targeted caspase inhibition in inflammatory diseases.
Gasdermin D-mediated delivery of caspase inhibitors to suppress pyroptosis
Why This Matters
This research highlights a novel approach to treating inflammatory diseases by leveraging Gasdermin D pores to deliver caspase inhibitors selectively into pyroptotic cells. This targeted delivery method could overcome previous challenges faced by cell-permeable inhibitors, offering a promising therapeutic strategy with potential applications in managing inflammatory conditions. The findings open new avenues for precise intervention in immune responses, benefiting both the tech industry developing advanced drug delivery systems and consumers seeking effective treatments.
Key Takeaways
- GSDMD pores enable selective delivery of caspase inhibitors into pyroptotic cells.
- This method prevents inflammation without affecting apoptosis, reducing side effects.
- Potential for targeted therapies in inflammatory diseases like endotoxic shock.
Get alerts for these topics